Loading...
Loading...
ONCT| Name | Value |
|---|---|
| Revenues | 569.0K |
| Cost of Revenue | 6,059.0K |
| Gross Profit | -5,490.0K |
| Operating Expense | 9,348.0K |
| Operating I/L | -8,779.0K |
| Other Income/Expense | 391.0K |
| Interest Income | 391.0K |
| Pretax | -8,388.0K |
| Income Tax Expense | -8,779.0K |
| Net Income/Loss | -8,388.0K |
Oncternal Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in developing oncology therapies for cancers with unmet medical needs. The company's clinical pipeline includes zilovertamab, a humanized monoclonal antibody targeting ROR1; ONCT-216, a small molecule inhibiting ETS-family transcription factor oncoproteins; ONCT-808, a CAR-T product targeting ROR1; and ONCT-534, an androgen receptor inhibitor for castration-resistant prostate and other cancers. Oncternal has license agreements with leading research institutions and a research collaboration with Celularity Inc. to evaluate placental derived-cellular therapies targeting ROR1.
